Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Takeda Secures US Approval For Myeloma Drug But It's Unlikely To KO Kyprolis

This article was originally published in Scrip

Executive Summary

The US FDA has approved Takeda Pharmaceutical Company's Ninlaro (ixazomib) – marking the entry of the first oral proteasome inhibitor into the multiple myeloma ring to battle against Johnson and Johnson and Genmab AS's recently approved first human anti-CD38 monoclonal antibody, Darzalex (daratumumab), as well as established therapies.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register